New radioactive drug aims to shrink hard-to-treat prostate cancer
NCT ID NCT07537010
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests a new drug called 3D1015 in men with a type of advanced prostate cancer that no longer responds to hormone therapy. The drug delivers radiation directly to cancer cells. The main goals are to check safety and find the best dose. About 8 men will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jiangnan University Affiliated Hospital
RECRUITINGWuxi, Jiangsu, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Chemo combo vs. radioactive drug: which tames aggressive prostate cancer?
- Can a new pill outsmart resistant prostate cancer?
- Can a radioactive 'Smart Bomb' outsmart advanced prostate cancer?
- Can an immune booster make hormone therapy work better against prostate cancer?
- Can a pill outsmart Tumors' defenses?
- Can targeted radiation tame advanced prostate cancer? a registry aims to find out